GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update
July 26 2022 - 9:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against infectious diseases and cancer, announces today that it
will report second quarter 2022 financial results on Wednesday,
August 3, 2022 after the market closes.
Management will host a conference call at 4:30 p.m. ET on
Wednesday, August 3, 2022 to review financial results and provide
an update on corporate developments. Following management’s formal
remarks, there will be a question-and-answer session.
Participants are asked to pre-register for the call via the
following link:
https://dpregister.com/sreg/10169470/f3bd71e646
Registered participants will receive their dial-in number upon
registration and will dial directly into the call without delay.
Those without Internet access or who are unable to pre-register may
dial in by calling 1-866-777-2509 (domestic) or 1-412-317-5413
(international). All callers should dial in approximately 10
minutes prior to the scheduled start time and ask to be joined into
the GeoVax call.
The conference call will be available through a live webcast
found here:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=A9WC5AAd
A webcast replay of the call will be available via the same link
as the live webcast approximately one hour after the end of the
call through November 3, 2022. A telephonic replay of the call can
be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088
(international) and using access code 1768209.
The telephonic replay will be available until August 17,
2022.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing human vaccines and immunotherapies against infectious
diseases and cancer using novel proprietary platforms. GeoVax’s
product pipeline includes two ongoing Phase 2 clinical trials of
GEO-CM04S1 (formerly COH04S1) for COVID-19 as a universal booster
vaccine to mRNA vaccines authorized by the U.S. Food and Drug
Administration (FDA) and as a primary vaccine for use in
immunocompromised patients. In addition to GEO-CM04S1 for COVID-19,
GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine. The
Company is also conducting a Phase 1/2 clinical trial of Gedeptin®
for treatment of head and neck cancer. Gedeptin® has been granted
orphan drug status by the FDA. Additional research and development
programs include preventive vaccines against Zika Virus,
hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and
malaria, as well as immunotherapies for multiple solid tumors. The
Company’s portfolio of wholly owned, co-owned, and in-licensed
intellectual property stands at over 70 granted or pending patent
applications spread over 20 patent families. For additional
information about GeoVax, visit our website: www.geovax.com.
Contact:GeoVax Labs,
Inc.investor@geovax.com678-384-7220
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Sep 2023 to Sep 2024